Sci Rep
November 19, 2019
Christopher Timmermann, Leor Roseman, Michael Schartner et al.
325 citations
Intravenous DMT, a fast-acting psychedelic, markedly reduces alpha and beta brain wave power and increases spontaneous signal diversity in the human brain, as measured by EEG. The emergence of delta and theta oscillatory activity correlates with the peak of the subjective experience, especially its eyes-closed visual component. Relationships between changes in subjective experience and brain activity were observed across time, linking specific brain changes to specific aspects of the experience.
Biological Psychiatry
January 10, 2014
Robin Carhart‐Harris, Kevin Murphy, Robert Leech et al.
182 citations
The medial temporal lobes (MTLs) are specifically involved in how MDMA works in the brain, though more research is needed to understand how the drug's characteristic subjective effects emerge from its modulation of spontaneous brain activity.
Psychopharmacology
November 26, 2018
Steliana Yanakieva, Naya Polychroni, Neiloufar Family et al.
169 citations
Microdoses of LSD (5, 10, and 20 μg) caused older adults to over-reproduce time intervals of 2000 milliseconds and longer, with the strongest effect at 10 μg. This temporal dilation occurred without noticeable changes in perception, mentation, or concentration, and was independent of any subjective drug effects. The findings suggest that LSD can directly alter interval timing at doses too low to produce conscious psychedelic effects, indicating a dissociation between neurochemical influences on time perception and altered states of consciousness.
Psychopharmacology
December 18, 2019
Neiloufar Family, Émeline L. Maillet, Luke T. J. Williams et al.
142 citations
Repeated low doses of LSD are safe and well tolerated in older adults. In a double-blind, placebo-controlled trial, 48 healthy volunteers aged around 63 received either 5, 10, or 20 micrograms of LSD or a placebo every four days for three weeks. LSD was undetectable in the blood at the 5 microgram dose, while peak levels for higher doses occurred within 30 minutes. Adverse events were no more frequent than with placebo, and tests of cognition, balance, and proprioception showed no impairment. These results support further clinical development of low-dose LSD for treating or preventing Alzheimer's disease.
Journal of Psychopharmacology
March 1, 2022
Neiloufar Family, Peter S. Hendricks, Luke T. J. Williams et al.
23 citations
LSD doses of 50, 75, and 100 micrograms are tolerable and safe in healthy adults when administered in a novel group-based intervention paradigm with one attendant per participant. Thirty-two adults (mean age 28.8 years) received LSD or placebo across open-label and double-blind designs. No serious adverse events occurred; 28% of participants reported at least one mild expected adverse event and one moderate event. Peak blood plasma levels appeared 1.2 to 2 hours after administration, with an apparent half-life of 2.8 to 4.3 hours. LSD produced greater subjective effects than placebo, including mystical-type experiences. Further research is needed in clinical populations.
Journal of Psychopharmacology
March 1, 2022
Peter S. Hendricks, Heith Copes, Neiloufar Family et al.
8 citations
In a proof-of-concept study with 31 healthy participants given 50 to 100 µg of LSD, most felt safe throughout the experiment, attributing their comfort to the study structure and support from attendants, which allowed them to let go and immerse themselves. A minority initially worried about having a challenging experience, but those concerns lessened over time. Participants reported transcendent, mystical-type experiences typical of classic psychedelics, with nearly half noting the important role of music during the drug's acute effects. They endorsed the clinical utility of LSD in controlled environments, believing it is safe and could help others. Findings suggest this scalable intervention paradigm is feasible and warrants further research with clinical populations.